Soleno Therapeutics, Inc. (SLNO)

NASDAQ: SLNO · IEX Real-Time Price · USD
36.85
-0.30 (-0.81%)
Apr 19, 2024, 2:55 PM EDT - Market open
-0.81%
Market Cap 1.19B
Revenue (ttm) n/a
Net Income (ttm) -38.99M
Shares Out 32.46M
EPS (ttm) -2.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 96,691
Open 36.86
Previous Close 37.15
Day's Range 36.85 - 37.90
52-Week Range 3.16 - 53.82
Beta -1.54
Analysts Strong Buy
Price Target 55.60 (+50.88%)
Earnings Date May 7, 2024

About SLNO

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, Califor... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 13, 2014
Employees 33
Stock Exchange NASDAQ
Ticker Symbol SLNO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for SLNO stock is "Strong Buy." The 12-month stock price forecast is $55.6, which is an increase of 50.88% from the latest price.

Price Target
$55.6
(50.88% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...

5 weeks ago - GlobeNewsWire

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

REDWOOD CITY, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment o...

6 weeks ago - GlobeNewsWire

Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

REDWOOD CITY, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment ...

2 months ago - GlobeNewsWire

Soleno Therapeutics to Present at Upcoming February Investor Conferences

REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment ...

2 months ago - GlobeNewsWire

Soleno Therapeutics Strengthens Leadership Team with Key Appointments

REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment ...

3 months ago - GlobeNewsWire

The best-performing stock of the year rose nearly 10-fold, while the second-best averted disaster to surge 1,000% in a wild 2023

No, it isn't related to artificial intelligence — although shares of AI-linked chip maker Nvidia Corp. NVDA, +0.16% have surged more than 200% thus far on the year.

Other symbols: CVNA
4 months ago - Market Watch

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

REDWOOD CITY, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...

5 months ago - GlobeNewsWire

Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open-Label Study of DCCR in Prader-Willi Syndrome

One-Year Administration of DCCR in PWS Patients from DESTINY-PWS Demonstrates Significant Improvements in Hyperphagia and Other Behavioral Complications One-Year Administration of DCCR in PWS Patients...

5 months ago - GlobeNewsWire

Correcting & Replacing -- Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium

In a press release issued earlier this afternoon, the time zone of the FPWR Research Symposium presentation was labeled as Central Time. The correct time zone is Mountain Time.

7 months ago - GlobeNewsWire

Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium

REDWOOD CITY, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for t...

7 months ago - GlobeNewsWire

Soleno Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

REDWOOD CITY, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq:SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics f...

7 months ago - GlobeNewsWire

Soleno Therapeutics Announces Pricing of Approximately $120 Million Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants

REDWOOD CITY, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq:SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics ...

7 months ago - GlobeNewsWire

Soleno Therapeutics Announces Proposed Public Offering of Common Stock and/or Pre-Funded Warrants and a Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants

REDWOOD CITY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq:SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics ...

7 months ago - GlobeNewsWire

Soleno Stock Dives After Its Meteoric Rise

The biotechnology company had announced positive study results for its DCCR tablets on Tuesday.

7 months ago - Barrons

Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome

Study Met Primary Endpoint; Highly Statistically Significant Difference in Change from Baseline in HQ-CT Total Score for DCCR Compared to Placebo (p=0.0022)

7 months ago - GlobeNewsWire

Soleno Therapeutics to Present at the Cantor Global Healthcare Conference

REDWOOD CITY, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...

7 months ago - GlobeNewsWire

Soleno Therapeutics Announces Appointment of Industry Veteran Matthew Pauls, J.D., M.B.A. to Board of Directors

REDWOOD CITY, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...

8 months ago - GlobeNewsWire

Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

REDWOOD CITY, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...

9 months ago - GlobeNewsWire

Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

REDWOOD CITY, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of ...

1 year ago - GlobeNewsWire

Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome

Top-line data expected in Q3 2023 and has the potential to support an NDA submission for DCCR in Prader Willi Syndrome

1 year ago - GlobeNewsWire

Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days

REDWOOD CITY, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...

1 year ago - GlobeNewsWire

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results

REDWOOD CITY, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment o...

1 year ago - GlobeNewsWire

Soleno Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference

REDWOOD CITY, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...

1 year ago - GlobeNewsWire

Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome

REDWOOD CITY, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment ...

1 year ago - GlobeNewsWire

Soleno Therapeutics Announces Financing Commitment for up to $60 Million

Funding from three leading healthcare investors, with Vivo Capital joining existing investors Nantahala Capital and Abingworth

1 year ago - GlobeNewsWire